spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck Introduces New Integrated Plug & Play Upstream Development Service

Merck


• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up
• Tailored upstream development from a single source reduces time to clinic by 20 percent
• Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment

July 17, 2019

Merck has launched its Plug & Play Upstream Development Service to help emerging biotech and start-up companies optimize the cost and speed of advancing their molecule to the clinical stage. Eliminating the need to work with multiple vendors for upstream development, the new service reduces bottlenecks, lowering time to clinic by two months. With 60 percent of drugs in the pipeline today being developed by emerging biotech companies, Merck’s tailored, streamlined service is poised to have a significant impact on drug development efficiency.

The Plug & Play Upstream Development Service includes:

• Cell line development, utilizing CHO cell lines or Merck’s proprietary CHOZN® license
• Standard analytics and early material from stable pools
• Stability study and clone selection

In the early stages of upstream development, cell line development and analytical development occur in parallel, allowing molecules to progress faster.

For customers looking to progress at an even faster speed, Merck offers its fast-track process by running process development and clone development steps in parallel, balancing speed and risk without sacrificing quality. The company’s robust and automated mini-pool approach allows it to more efficiently generate early material for process development, reducing the timeline by 10 weeks for the first pharmacodynamic experiment at the pre-clinical stage.

Customers are supported by a dedicated project manager and Merck expertise including risk assessment and regulatory expertise. Monoclonality and stability validation is fully documented based on regulatory expectations and a statistical approach. There are no royalty fees and customers have the freedom to technology transfer at any stage, to any partner.

Optional, add-on plug and play services are available, depending on customers’ needs, including:

• Off-the-shelf media and feed screening
• Analytical method development
• Complete analytics
• GMP master cell bank (MCB) and cell bank characterization
• MCB storage

Customers also have the option for Merck's BioReliance® Product Characterization team to synthesize data from multiple analytical and bioanalytical methods to help reveal the true identity of the product, ensuring the biotherapy’s safety, purity and potency with off-the-shelf mAb-based assay packages or a custom assay tailored for the biologic. Based on the mAbs needs, the product characterization team would recommend vital assays to provide all key physiochemical, binding and functional critical quality attributes and selects the lead clone for the generation of the desired product.

The Plug & Play Upstream Development Service demonstrates how Merck's BioReliance® End to End Solutions help companies realize their drug development goals. With more than 32 years of experience and over 250 biomolecules, this group helps small-sized biotech companies and start-ups at all stages from molecule development towards commercialization—in any geography— to address key challenges.
phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Gerresheimer manufactures sustainable primary plastic packaging

Düsseldorf, January 14, 2020. Consumers are placing great importance on eco-friendly plastic packaging products, specifically – and increasingly – on sustainable packaging solutions that can be disposed of in an environmentally friendly way. At Gerresheimer, therefore, innovation and environmental protection go hand in hand. A pioneer in the quest for greater sustainability, Gerresheimer offers an extensive standard range of plastic packaging and devices customized solutions made from PET, R-PET, and BIO-PET plastics.
More info >>


White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement